1
UI - 10774080
AU - Opot EN; Magoha GA
TI -
Testicular cancer at Kenyatta National Hospital, Nairobi.
SO - East Afr Med J 2000 Feb;77(2):80-5
AD - Department of Surgery, College of Health Sciences, University of
Nairobi.
OBJECTIVE: To determine the prevalence, clinical characteristics,
management methods and prognosis of testicular cancer at Kenyatta
National Hospital. DESIGN: Retrospective case study of testicular cancer
patients over a fifteen year period. SETTING: Kenyatta National
Hospital, a referral and teaching hospital. PARTICIPANTS: All
histologically confirmed testicular cancer patients recorded at the
Histopathology Department of Kenyatta National Hospital between 1983 and
1997. RESULTS: The mean age was 34.8 years with a peak incidence in the
30-44 year age group. History of cryptochirdism was obtained in 10.26%
of the patients. Thirty one patients (79.49%) presented with painless
testicular swellings, eleven (28.08%) with pain, nine (23.08%) with
scrotal heaviness, six (15.38%) with abdominal swellings and one (2.56%)
each with gynaecomastia and eye swelling. On examination 32 patients
(82.05%) had testicular masses, ten (25.64%) had abdominal masses, seven
(17.91%) had supraclavicular and cervical lymphadenopathy, and one each
(2.56%) had gynaecomastia and eye mass respectively. More than eighty
nine per cent had germ cell cancers with seminoma accounting for 67.35%,
teratoma 12.24%, embroyonal carcinoma 8.16%, rhabdomyosarcoma 6.12% and
malignant germ cell tumour, orchioblastoma and dysgerminoma each
accounted for 2.04%. Three patients (7.7%) had orchidectomy and
radiotherapy and chemotherapy, sixteen (41.03%) had orchidectomy and
radiotherapy, six (15.38%) had orchidectomy and chemotherapy, ten
(25.64%) had radiotherapy and chemotherapy, three (7.7%) and two (5.13%)
had only chemotherapy and radiotherapy respectively. No cisplastin based
chemotherapy regime was used. Follow up was effected for eighteen
patients (46.15%) and seven patients (38.89%) were alive after five
years. CONCLUSION: Prognosis with current regimes was poor with survival
of only 38.89% after five years. Cisplastin based chemotherapy with up
to 90% cure rates should be included as a component of testicular cancer
management at Kenyatta National Hospital.
2
UI - 12175407
AU - Geldart TR; Simmonds PD; Mead GM
TI -
Orchidectomy after chemotherapy for patients with metastatic testicular
germ cell cancer.
SO - BJU Int 2002 Sep;90(4):451-5
AD - Wessex Medical Oncology Unit, Southampton University Hospitals,
Southampton, UK. tom.geldart@talk21.com
OBJECTIVE: To evaluate the contribution of routine orchidectomy in the
management of patients who present with advanced, metastatic, testicular
germ cell cancer and who are treated with initial chemotherapy. PATIENTS
AND METHODS: Sixty consecutive patients presenting with metastatic
testicular germ cell cancer and treated with initial chemotherapy
followed by orchidectomy were identified. The results from a clinical
and pathological review of these patients are presented. The
pathological findings at orchidectomy were compared with the
pathological findings from metastatic masses resected after
chemotherapy, and are reviewed with the clinical outcome. RESULTS: Of
the 60 orchidectomy specimens after chemotherapy, 24 (40%) contained
significant histological abnormalities comprising residual invasive germ
cell cancer, intratubular germ cell neoplasia and/or mature teratoma.
The remaining 36 (60%) orchidectomy specimens contained fibrous scarring
with or with no necrosis. Six (10%) orchidectomy specimens contained
residual invasive germ cell cancer, three nonseminomatous germ cell
cancer (NSGCT) and three seminoma. The patients with residual invasive
NSGCT present within the testis had evidence of residual invasive NSGCT
within extragonadal masses resected after chemotherapy; all three have
relapsed and died from chemorefractory progressive disease. CONCLUSION:
Orchidectomy after chemotherapy is recommended in all patients
undergoing primary chemotherapy, as a significant proportion (40%) are
left with histological abnormalities that predispose to subsequent
relapse. Persistence of invasive NSGCT at the site of the primary tumour
after chemotherapy is associated with persistence of invasive disease at
other metastatic sites and is a poor prognostic finding.
3
UI - 2319701
AU - Mori M; Davies TW; Miyake H; Masuoka H; Kumamoto Y; Tsukamoto T
TI -
Maternal factors of testicular cancer: a case-control study in Japan.
SO - Jpn J Clin Oncol 1990 Mar;20(1):72-7
AD - Department of Public Health, Sapporo Medical Cllege.
A case-control study was undertaken in Japan to clarify maternal or
prenatal factors associated with testicular cancer. Information was
obtained from 37 mothers of testicular cancer patients, recruited from
the discharge records of nine hospitals in Hokkaido, the northern island
of Japan. Thirty-seven mothers forming a control group were then
surveyed at five public health centers. Each control was selected by
individually matching the sex and birth year to a testicular cancer
case. Univariate analysis revealed that there were no statistically
significant differences in the variables surveyed. Multivariate logistic
regression analysis, however, showed that case mothers had significantly
fewer live-births than control mothers when the following four variables
were adjusted (adjusted relative risk per live-birth = 0.43, P = 0.025):
age at indexed birth, duration of breast-feeding for indexed child,
birth order, experience of induced abortion.
4
UI - 2106990
AU - Cale AR; Farouk M; Prescott RJ; Wallace IW
TI -
Does vasectomy accelerate testicular tumour? Importance of testicular
examinations before and after vasectomy.
SO - BMJ 1990 Feb 10;300(6721):370
AD - Bangour General Hospital, West Lothian.
5
UI - 1571679
AU - Nienhuis H; Goldacre M; Seagroatt V; Gill L; Vessey M
TI -
Incidence of disease after vasectomy: a record linkage retrospective
cohort study.
SO - BMJ 1992 Mar 21;304(6829):743-6
AD - Unit of Clinical Epidemiology, University of Oxford.
OBJECTIVE--To determine whether vasectomy is associated with an
increased risk of several diseases, and in particular testicular cancer,
after operation. DESIGN--Retrospective cohort study using linked medical
record abstracts. SETTING--Six health districts in Oxford region.
SUBJECTS--13,246 men aged 25-49 years who had undergone vasectomy
between 1970 and 1986, and 22,196 comparison subjects who had been
admitted during the same period for one of three specified elective
operations, appendicitis, or injuries. MAIN OUTCOME MEASURES--Hospital
admission and death after vasectomy or comparison event. RESULTS--The
mean durations of follow up were 6.6 years for men with a vasectomy and
7.5 years for men with a comparison condition. The relative risk of
cancer of the testis in the vasectomy cohort (4 cases) compared with
that in the other cohorts (17 cases) was 0.46 (95% confidence interval
0.1 to 1.4), that of cancer of the prostate (1 v 5 cases) 0.44 (0.1 to
4.0), and that of myocardial infarction (97 v 226 cases) 1.00 (0.8 to
1.3). There was no evidence of an increase associated with vasectomy in
the incidence of a range of other diseases. CONCLUSIONS--Vasectomy was
not associated with an increased risk of testicular cancer or the other
diseases studied. With respect to prostatic cancer, while we found no
cause for concern, longer periods of observation on large numbers of men
are required.
6
UI - 8518871
AU - Hewitt G; Logan CJ; Curry RC
TI -
Does vasectomy cause testicular cancer?
SO - Br J Urol 1993 May;71(5):607-8
AD - Department of Surgery, Ulster Hospital, Belfast.
Between 1975 and 1990, 330 men developed testicular tumours in Northern
Ireland. Their names were cross matched with a sample of 2904 men who
had undergone vasectomy between 1970 and 1985. The expected numbers of
tumours in vasectomised patients was 2, while the actual number was 1.
Our experience does not indicate that vasectomy causes testicular
cancer.
7
UI - 3580788
AU - Thornhill JA; Butler M; Fitzpatrick JM
TI -
Could vasectomy accelerate testicular cancer? The importance of
pre-vasectomy examination.
SO - Br J Urol 1987 Apr;59(4):367
8
UI - 6140323
AU - Depue RH; Pike MC; Henderson BE
TI -
Estrogen exposure during gestation and risk of testicular cancer.
SO - J Natl Cancer Inst 1983 Dec;71(6):1151-5
In this case--control study of 108 cases of testicular cancer in men
under 30 years of age, cryptorchidism was a major risk factor [relative
risk (RR) = 9.0]. Low birth weight was also associated with increased
risk (RR = 3.2). Having severe acne at puberty was protective (RR =
0.37). Interviews with mothers of cases revealed that exposure of the
mother to exogenous estrogen during pregnancy created a significant risk
in the son (RR = 8.0). In first pregnancies, excessive nausea indicated
an increased risk of testicular cancer (RR = 4.2). Increased body weight
in the mother also increased the risk. The relation between these
factors and testicular hypoplasia is discussed. Severe perimenopausal
menorrhagia was a factor in the mother associated with reduced risk of
testicular cancer in the son (RR = 0.10). A modified hormonal milieu in
the mother appears to be important in the later development of
testicular cancer in her sons.
9
UI - 2837898
AU - Strader CH; Weiss NS; Daling JR
TI -
Vasectomy and the incidence of testicular cancer.
SO - Am J Epidemiol 1988 Jul;128(1):56-63
AD - Hanford Environmental Health Foundation, Richland, WA.
Adult male residents of 13 counties of western Washington state in whom
testicular cancer had been diagnosed during 1977-1983 (n = 333) were
interviewed over the telephone regarding their history of genital tract
conditions, including vasectomy. For comparison, the same interview was
given to a sample of 729 men selected from the population of these
counties by dialing telephone numbers at random. A higher proportion of
cases than controls reported having had a vasectomy (relative risk =
1.5, 95 per cent confidence interval = 1.0-2.2). However, the
association was restricted entirely to Catholic men. Whereas a history
of vasectomy was reported with approximately equal frequency by Catholic
and non-Catholic cases, only 6.3 per cent of Catholic controls reported
such a history in contrast to 19.7 per cent of other controls. While the
authors cannot rule out the possibility that there is a true difference
of the effect of vasectomy on the incidence of testicular cancer as a
function of religion, it seems more plausible that selective
underreporting by Catholic controls has produced a spurious relation.
10
UI - 3177126
AU - Mori M; Miyake H; Kumamoto Y; Tsukamoto T; Saitoh S; Enatsu C; Tamiya T;
TI -
Tanda H; Fujita M; Honma A; et al
[A case-control study of testicular cancer]
SO - Hinyokika Kiyo 1988 May;34(5):832-8
AD - Department of Public Health, Sapporo Medical College.
A study on the possible association of maternal factors with testicular
cancer was undertaken. Information was obtained from the mothers of
testicular cancer cases (N = 37) and the mothers of men without the
disease (N = 37). Comparisons were made between the two groups. The
cases were collected from the records of nine hospitals, and the
controls were selected from five Public Health Centers by individually
matching the sex and the year of birth with the testicular cancer cases.
The mothers of the cases had significantly fewer live births than the
mothers of the controls (the adjusted odds ratio per live birth = 0.4, p
= 0.02), when the five following variables had been simultaneously
adjusted by the logistic regression analysis. Those five variables
included the Quetelet's Index of mothers before pregnancy, the age at an
index birth, the duration of breastfeeding for an index child, the birth
order of an index child, and the number of induced abortions. The
endogenous hormonal milieu of a mother may be associated with the
occurrence of testicular cancer in her child.
11
UI - 1737197
AU - Moul JW
TI -
Inappropriate surgery for testicular cancer.
SO - Br J Hosp Med 1992 Jan 9-22;47(1):73
12
UI - 1294070
AU - Oliver RT; Raja MA
TI -
Rapid diagnosis of testicular tumour.
SO - Br J Hosp Med 1992 Feb 19-Mar 3;47(4):304
13
UI - 12201940
AU - Harper M; Arya M; Peters JL; Buckingham S; Freeman A; O'Donoghue EP
TI -
Intratesticular lipoma.
SO - Scand J Urol Nephrol 2002;36(3):223-4
AD - Institute of Urology & Nephrology, University College London, London,
UK. matthewharper@totalise.co.uk
Benign intratesticular lesions are rare. We describe the second reported
case of an intratesticular lipoma and discuss the limitations of
ultrasonography in differentiating benign from malignant conditions
occurring within the testis.
14
UI - 11925418
AU - Schrader M; Muller M; Sofikitis N; Straub B; Miller K
TI -
Testicular sperm extraction in azoospermic cancer patients prior to
treatment--a new guideline?
SO - Hum Reprod 2002 Apr;17(4):1127-8
15
UI - 11957559
AU - Lim LP; Tan AM; Chan MY; Rajalingam V; Lou J; Tan CL
TI -
Paediatric extracranial germ cell tumours: a retrospective review.
SO - Ann Acad Med Singapore 2002 Mar;31(2):206-11
AD - Haematology/Oncology Service, Department of Paediatric Medicine, KK
Women's & Children's Hospital, 100 Bukit Timah Road, Singapore 229899.
lillianl@kkh.com.sg
INTRODUCTION: Germ cell tumours (GCTs) are rare, constituting 3% of all
childhood malignancies. The aim of this study was to analyse the
epidemiology and outcome of these patients. MATERIALS AND METHODS: A
retrospective, cohort study was conducted on 38 paediatric patients
presenting with extracranial GCTs, treated at the Singapore General
Hospital, Tan Tock Seng Hospital and Kandang Kerbau Women's and
at diagnosis was 1.7 years (0 to 13 years). RESULTS: There was no sex or
racial preponderance. Eighteen patients (47.3%) had teratomas, 16
(42.1%) had yolk sac tumours, 1 (2.6%) had dysgerminoma and 3 (7.9%) had
mixed GCTs. Thirty-four patients (89.5%) had Stage I disease, 1 (2.6%)
had Stage II disease, 1 (2.6%) had Stage III disease and 2 (5.3%) had
metastatic disease. Complete tumour resection was achieved in 36 of the
38 patients (95%). Cisplatin-based combination chemotherapy was given to
11 patients (28.9%). None of the patients received radiotherapy.
Complications from chemotherapy included anaemia requiring packed red
cell transfusion (n = 3), Port-a-cath sepsis requiring removal (n = 1),
febrile neutropenia (n = 1) and nephropathy (n = 1). CONCLUSION: Using
the Kaplan-Meier life tables, the overall and event-free survivals at 10
years for the patients with malignant GCTs were 96% and 88%,
respectively, with a mean follow-up period of 5.1 years (0.7 to 10
years). The majority of the patients presented with early Stage I
disease and this contributed to our high survival rate.
16
UI - 11896104
AU - Kersemaekers AM; Mayer F; Molier M; van Weeren PC; Oosterhuis JW;
TI -
Bokemeyer C; Looijenga LH
Role of P53 and MDM2 in treatment response of human germ cell tumors.
SO - J Clin Oncol 2002 Mar 15;20(6):1551-61
AD - Department of Pathology/Laboratory for Experimental Patho-Oncology,
University Hospital Rotterdam/Daniel, Josephine Nefkens Institute,
Erasmus University Rotterdam, Rotterdam, The Netherlands.
PURPOSE: Testicular germ cell tumors (TGCTs) of adolescents and adults
are very sensitive to systemic treatment. The exquisite chemosensitivity
of these cancers has been attributed to a high level of wild-type P53.
MATERIALS AND METHODS: To clarify the role of P53 in treatment
sensitivity and resistance of TGCTs, we performed immunohistochemistry
and Western blotting analysis on a series of 39 fresh-frozen primary
TGCTs before therapy (unselected series). In a series of formalin-fixed
paraffin-embedded TGCTs of patients with fully documented clinical
course, including treatment-sensitive (n = 17) and -resistant (n = 18)
tumors, P53 status was assessed by immunohistochemistry and mutation
analysis. In addition, the involvement of MDM2, a P53 antagonist, was
investigated by immunohistochemistry, reverse transcriptase polymerase
chain reaction, and in situ hybridization. RESULTS: Immunohistochemistry
demonstrated absence of staining for P53 in 36%, 41%, and 17% of the
unselected, responding, and nonresponding TGCTs, respectively. Of the
positive TGCTs, most tumors, ie, 49%, 41%, and 33%, showed 1% to 10%
positive nuclei. This overall low level of P53 was confirmed by Western
blotting. Mutation analysis revealed only one silent P53 mutation in one
of the responding patients. All embryonal carcinomas were homogeneously
positive for MDM2, encoded by the full length mRNA, while a
heterogeneous pattern was found for the other histologic components.
Amplification of MDM2 was detected in one out of 12 embryonal
carcinomas. CONCLUSION: Although our results are in line with previous
findings of the presence of wild-type P53 in TGCTs, they show that a
high level of P53 does not relate directly to treatment sensitivity of
these tumors, and inactivation of P53 is not a common event in the
development of cisplatin resistance.
17
UI - 12149951
AU - Drognitz O; Pfeiffenberger J; Schareck W; Adam U; Nizze H; Hopt UT
TI -
[Primary aortoduodenal fistula as a late complication of para-aortic
radiation therapy. A case report]
SO - Chirurg 2002 Jun;73(6):633-7
AD - Abteilung fur Allgemeine Chirurgie und Visceralchirurgie, Klinik und
Poliklinik fur Chirurgie, Albert-Ludwigs-Universitat Freiburg i.Br.,
Hugstetter Strasse 55, 79106 Freiburg i.Br. drognitz@uni-freiburg.de
Primary aortoenteric fistulae (AEFs) are rare vascular entities. More
than 75% of primary AEFs involve the duodenum, with the overwhelming
majority located in the third or fourth portion. Atherosclerosis,
leading to formation of an aortic aneurysm, remains the most common
etiology, accounting for more than 3/4 of the cases reported. Primary
aortoenteric fistulae following radiotherapy are rare. The case of a
49-year-old man with aortoduodenal fistula 22 years after para-aortic
hematemesis and melena. Endoscopy suggested the presence of an ulcus but
no definitive bleeding source could be seen. Bleeding stopped
spontaneously. Six hours later he developed massive hematemesis and was
transferred to our department. An emergency operation was performed. We
found an aorto-duodenal fistula in the third portion of the duodenum
without an aortic aneurysm. We directly sutured the aortic wall
laceration and resected the third and fourth part of the duodenum.
Histology revealed typical signs of radiation damage. The patient is
alive and well 2 years after surgery. To our knowledge, this is the
sixth case of a primary aorto-duodenal fistula following radiotherapy
ever to be reported in world literature.
18
UI - 12188077
AU - Kok KY; Telesinghe PU
TI -
Lymphangioma of the epididymis.
SO - Singapore Med J 2002 May;43(5):249-50
AD - Department of Surgery, Ripas Hospital, Brunei Darussalam. koky@brunet.bn
We report herein a 39-year-old man with a left scrotal swelling.The
clinical and ultrasonographic appearances were suggestive of epididymal
cyst. Histopathology of the excised lesion was shown to be lymphangioma
of the epididymis.The differential diagnoses of a swelling in the
scrotum of a young man include both benign and malignant conditions.
Lymphangioma of the epididymis is, however, a rare and unusual cause.
19
UI - 12196237
AU - Hruby G; Choo R; Jackson M; Warde P; Sandler H
TI -
Management preferences following radical inguinal orchidectomy for Stage
I testicular seminoma in Australasia.
SO - Australas Radiol 2002 Sep;46(3):280-4
AD - Department of Radiation Oncology, Royal Prince Alfred Hospital, Sydney,
New South Wales, Australia. ghruby@email.cs.nsw.gov.au
A survey to evaluate the preferred patterns of management of Stage I
distributed by the Royal Australian and New Zealand College of
Radiologists to all qualified radiation oncologists, 74 out of 170
responded. All performed a staging CT scan of the abdomen and pelvis.
Thoracic imaging consisted of either chest X-ray (29%) or chest CT (38%)
while 33% performed both. Fifty-four percent of radiation oncologists
discussed surveillance with their patients but estimated that 5% or less
would choose this option. The most commonly prescribed dose was 25 Gy in
15 or 20 fractions (79%). Sixty-five percent of respondents treated the
para-aortic (PA) nodes alone. Forty-two of 48 clinicians treating the PA
field reported a change in practice after publication of the Medical
Research Council study in 1999. Of these, 40 and 23% perform CT scans of
the pelvis annually and every 6 months. Thirty-one percent did no
follow-up CT scan. Compared to a similar survey from North America, we
are more likely to use PA fields and less likely to discuss
surveillance. As in the USA, and in contrast to Canada, few patients
choose surveillance. There is no consensus regarding the frequency of
follow-up scans in either North America or Australasia.
20
UI - 12237987
AU - Wynd CA
TI -
Testicular self-examination in young adult men.
SO - J Nurs Scholarsh 2002;34(3):251-5
AD - University of Akron, 209 Carroll Street, Akron, OH 44325-3701, USA.
cwynd@uakron.edu
PURPOSE: To describe patterns of testicular self-examination (TSE) in a
sample of young adult men and to identify factors distinguishing between
men who do and do not practice TSE. DESIGN: A comparative descriptive
design with a convenience sample of 191 adult men aged 18-35 years,
recruited from a large industrial complex in the U.S. Midwest. Data were
collected during several occupational health fairs held from 1999-2001.
METHODS: A self-report, 75-item health risk appraisal (HRA) was
administered to identify health-related lifestyle habits. Men who did
and did not perform TSE regularly were compared using Mann-Whitney U
statistics for discrete variables and t tests for continuous data.
Discriminant function analysis was used to identify factors allowing
prediction of frequent or infrequent TSE performance. FINDINGS:
Sixty-four percent of 191 participants reported rarely or never
performing TSE, and 36% practiced TSE monthly or every few months. Men
who infrequently performed TSE were more often African American or
Hispanic and had less than a college education. Other significant
factors associated with infrequent TSE practice included less
satisfaction with current job assignment; less satisfaction with life in
general; greater worries interfering with daily life; more serious
family problems in dealing with spouse, children, or parents; and
reduced availability of people to turn to for support. CONCLUSIONS:
Demographic and socioeconomic variables were related to TSE knowledge
and performance. Further investigation is required to determine why men,
especially ethnic minority men, are not performing this important
cancer-screening activity.
21
UI - 12240866
AU - Talwar V; Sreedharan PS; Warrier NK; Ramanan SG; Sagar TG
TI -
Intracardiac metastases from a testicular germ cell tumor.
SO - J Assoc Physicians India 2002 Jun;50():855
AD - Department of Medical Oncology, Cancer Institute, Adyar, Chennai.
22
UI - 11763316
AU - Albanese JM; Reuter VE; Bosl GJ; Houldsworth J; Chaganti RS
TI -
Expression of ID genes in differentiated elements of human male germ
cell tumors.
SO - Diagn Mol Pathol 2001 Dec;10(4):248-54
AD - Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York,
New York 10021, USA.
The ID genes are members of a family of genes that encode
helix-loop-helix (HLH)-containing proteins. The Id proteins, unlike
other HLH proteins, lack an adjacent DNA binding domain and hence act as
dominant negative regulators of HLH transcription factors that have been
implicated in control of cellular differentiation. Although the role of
Id genes in murine development has been documented, their roles in human
embryogenesis remain unknown. In this study, human male germ cell tumors
(GCTs) were used as a model for examining the expression of the ID genes
in various histologies that are reflective of different temporal phases
of human development. In seminomas, little or no expression of IDI, ID2,
and ID3 was detected, consistent with the uncommitted germ cell-like
phenotype of this tumor histology. Likewise, GCTs with histologies
reflective of extraembryonic and embryonic patterns of differentiation
exhibited patterns of expression of the three ID genes often similar to
those noted during murine development. It was also evident, as revealed
by ID expression patterns, that despite the overall aberrant spatial
differentiation patterns displayed by these tumors, some tissue-tissue
interactions reminiscent of those observed during normal embryogenesis
are retained. Thus, adult male GCTs offer a unique system in which the
role of genes such as the IDs can be studied in human embryogenesis.
23
UI - 12352332
AU - Ross JH; Rybicki L; Kay R
TI -
Clinical behavior and a contemporary management algorithm for
prepubertal testis tumors: a summary of the Prepubertal Testis Tumor
Registry.
SO - J Urol 2002 Oct;168(4 Pt 2):1675-8; discussion 1678-9
AD - Section of Pediatric Urology, Cleveland Clinic Urological Institute and
Cleveland Clinic Department of Biostatistics and Epidemiology,
Cleveland, OH, USA.
PURPOSE: The Prepubertal Testis Tumor Registry was established by the
Urologic Section of the American Academy of Pediatrics in 1980 to record
data on a large number of prepubertal testis tumors regarding
presentation, treatment and outcome to define appropriate management
better. We reviewed the registry data in the context of other modern
studies to elucidate the appropriate management of these rare tumors.
MATERIALS AND METHODS: Relevant data in the prepubertal testis tumor
registry were tabulated and analyzed. RESULTS: There were 395
prepubertal patients who had a primary testis tumor. Generally benign
tumors accounted for 38% of cases. A significant proportion of tumors
were benign regardless of patient age. alpha-Fetoprotein levels for
patients with benign and malignant tumors overlapped in children younger
than 6 months. Of the patients with yolk sac tumor 80% presented with
stage 1 disease and overall survival was excellent. There were no
metastases or deaths among the patients with teratoma. Of all patients
with stromal tumors metastases developed in only 1. CONCLUSIONS: We
recommend initial excisional biopsy for all amenable prepubertal testis
tumors, except those with an alpha-fetoprotein level that is clearly
increased for patient age. Patients with benign tumors may be released
from oncological followup. Patients with stage I yolk sac tumor should
be monitored closely, and those with recurrent or metastatic yolk sac
tumor should be treated with chemotherapy. Retroperitoneal lymph node
dissection is reserved for patients with recurrent retroperitoneal
masses following chemotherapy. Aggressive treatment of metastatic
Sertoli cell or undifferentiated stromal tumors is warranted.
24
UI - 11893462
AU - Bhalla RK; Jones TM; Errington D; Roland NJ
TI -
Metastatic testicular seminoma--a case report.
SO - Auris Nasus Larynx 2002 Apr;29(2):219-22
AD - Department of Otolaryngology, University Hospital Aintree, Lower Lane,
L9 7AL, Liverpool, UK. drrkbhalla@doctors.org.uk
We present the case of a 42-year-old male who presented with a hot,
tender swelling in the left supraclavicular fossa. He was pyrexial on
presentation with a mildly elevated leucocyte count of 12.4x10(9)/l.
Clinical examination, including full ear, nose and throat assessment,
proved unremarkable. The medical history revealed that 2 years earlier
the patient had been diagnosed with a testicular seminoma for which he
underwent a right inguinal orchidectomy and abdominal radiotherapy. CT
scan highlighted a 6 cm para-laryngeal mass, of mixed attenuation, with
an adjacent region of inflammation. Overall appearance was suggestive of
an infective mass. Ultrasound-guided fine needle aspiration cytology
revealed a metastatic seminomatous deposit. Imaging of the chest and
abdomen revealed this as the only site of metastasis. He is currently
undergoing chemotherapy, and is responding well. We review the pathology
of testicular seminoma. This case highlights the myriad of pathologies
that may present as a lump in the neck.
25
UI - 12228753
AU - Foster R; Bihrle R
TI -
Current status of retroperitoneal lymph node dissection and testicular
cancer: when to operate.
SO - Cancer Control 2002 Jul-Aug;9(4):277-83
AD - Department of Urology, Indiana University School of Medicine,
Indianapolis, IN 46202, USA. rsfoster@iupui.edu
BACKGROUND: Historically, retroperitoneal lymph node dissection (RPLND)
has been used in the therapy of both low-stage and high-stage testicular
cancer after chemotherapy. As other therapies have developed, the role
of RPLND has also evolved. METHODS: The authors review the current
indications for RPLND in the therapy of testicular cancer. RESULTS:
Metastatic testicular cancer can be cured in 50% to 75% of cases by
surgical removal using RPLND, depending on the volume of metastasis. In
postchemotherapy disease, the surgical removal of teratoma or carcinoma
also confers a therapeutic benefit to the patient. CONCLUSIONS: The
therapeutic capability of RPLND in low-stage testicular cancer is
underappreciated. In postchemotherapy disease, this therapeutic
capability is retained if the patient has carcinoma or teratoma in the
metastatic tumor. In postchemotherapy disease, efforts continue to
appropriately select patients preoperatively who have only fibrosis and
necrosis in the specimen and therefore do not derive therapeutic benefit
from RPLND.
26
UI - 12228759
AU - Shvarts O; Han KR; Seltzer M; Pantuck AJ; Belldegrun AS
TI -
Positron emission tomography in urologic oncology.
SO - Cancer Control 2002 Jul-Aug;9(4):335-42
AD - Department of Urology, University of California Los Angeles School of
Medicine, Los Angeles, Calif 90095, USA.
BACKGROUND: Positron emission tomography (PET) is an emerging imaging
modality that is being investigated for use in urologic oncology. PET
scanning using the radioactive glucose analog FDG has proven to be a
highly accurate imaging test for diagnosing and staging a variety of
non-urologic cancer types. This review was performed to determine the
role of PET imaging in genitourinary malignancies. METHODS: A review of
the literature focusing on PET and urologic oncology was performed. The
role of PET imaging was reviewed in prostate, bladder, renal, and
testicular cancer. RESULTS: In testicular cancer, PET has a higher
diagnostic accuracy than computed tomography (CT) for both staging and
re-staging and should be the test of choice for the assessment of a
CT-visualized residual mass following chemotherapy. In prostate, renal,
and bladder cancer, the current role of PET is still being defined, but
it has a high positive predictive value and can be used for problem
solving in patients with indeterminate findings on conventional imaging.
Its role in the diagnosis and staging of prostate cancer is hampered by
the generally low glycolytic rate of most prostate tumors and their
metastases. It has shown promise for staging and re-staging patients
with advanced-stage disease and aggressive tumors suspected by a high
tumor grade and high prostate-specific antigen velocity. PET has also
demonstrated success when applied to renal cell carcinoma in classifying
indeterminate renal masses as well as residual renal fossa masses
following nephrectomy, gauging response to therapy, and staging and
re-staging patients with a known diagnosis of renal cell carcinoma.
CONCLUSIONS: PET imaging has demonstrated great potential in certain
applications, but further investigations are necessary to determine its
eventual place as an imaging modality in genitourinary malignancies.
27
UI - 12352400
AU - Ohyama C; Chiba Y; Yamazaki T; Endoh M; Hoshi S; Arai Y
TI -
Lymphatic mapping and gamma probe guided laparoscopic biopsy of sentinel
lymph node in patients with clinical stage I testicular tumor.
SO - J Urol 2002 Oct;168(4 Pt 1):1390-5
AD - Department of Urology, Tohoku University School of Medicine, Sendai,
Japan.
PURPOSE: We attempted to detect lymphatic drainage and sentinel lymph
node with radioactive tracer in patients with testicular tumor. We then
tried to determine if sentinel lymph node biopsy with gamma probe guided
laparoscopic procedure was feasible as a staging tool for patients with
clinical stage I testicular tumor. MATERIALS AND METHODS:
Technetium-labeled phytate was injected around the tumor in 15
consecutive patients with clinical stage I testicular tumor. Lymphatic
drainage and sentinel lymph nodes were imaged by a gamma camera.
Localization of the sentinel lymph node was confirmed with a handheld
gamma probe. After we confirmed that sentinel lymph nodes were detected
in the initial 10 patients, gamma probe guided laparoscopic sentinel
lymph node biopsy was performed after routine orchiectomy in the next 4.
To confirm whether the radioactive node was really a sentinel lymph node
the final patient in this series underwent laparoscopic retroperitoneal
lymph node dissection with a unilateral template. RESULTS: Sentinel
lymph nodes were detected in all patients by lymphoscintigraphy and
handheld gamma probe, and each node varied. Right tumors in sentinel
lymph node were detected at the inter-aortocaval, paracaval or common
iliac region. Para-aortic lymph nodes were detected as sentinel lymph
node in cases of left tumor. In the 4 patients who underwent gamma probe
navigated laparoscopic procedure sentinel lymph nodes were easily
detected and safely removed for pathological examination. In the last
patient who underwent laparoscopic lymph node dissection micrometastasis
was found only at the sentinel lymph node. CONCLUSIONS: Sentinel lymph
node can be detected by lymphoscintigraphy and handheld gamma probe.
Gamma probe guided laparoscopic biopsy of sentinel lymph node is
technically possible. These techniques may have a role in the management
of clinical stage I testicular tumor but further trials are required for
establishment of the concept of sentinel lymph node in testicular tumor.
28
UI - 12352401
AU - Langenstroer P; Rosen MA; Griebling TL; Thrasher JB
TI -
Ejaculatory function in stage T1 nonseminomatous germ cell tumors:
retroperitoneal lymph node dissection versus surveillance--a decision
analysis.
SO - J Urol 2002 Oct;168(4 Pt 1):1396-401
AD - University of Kansas Medical Center, Kansas City, USA.
PURPOSE: Ejaculatory function remains a major concern for patients with
low stage nonseminomatous germ cell tumors of the testis. Whereas, it
has been extensively studied in patients undergoing retroperitoneal
lymph node dissection, preservation of ejaculatory function on
surveillance protocols has not been studied. To compare ejaculatory
function for surveillance protocols to primary retroperitoneal lymph
node dissection appropriately, we constructed a decision analysis model
mimicking the standard treatment algorithm for stage 1 nonseminomatous
germ cell tumor of the testis. MATERIALS AND METHODS: The primary
clinical payoff for this study is ejaculatory function. Based on this
model, we established that a primary nerve sparing retroperitoneal
dissection must be performed with a 96.8% ejaculatory function rate to
be recommended as the appropriate therapy. However, if a highly skilled
surgeon routinely performs post-chemotherapy dissection with an
ejaculatory function rate of 69.2% or greater, surveillance should be
offered as the primary treatment modality. This result simply
demonstrates a high skill level to allow the surgeon to salvage
ejaculatory function in post-chemotherapy retroperitoneal lymph node
dissection settings. If this level cannot be achieved, primary
retroperitoneal lymph node dissection is the best choice. If we account
for a 10% loss of ejaculatory function from primary chemotherapy, the
minimum ejaculatory function rate for primary retroperitoneal dissection
decreases to 95.7%. RESULTS: In the post-chemotherapy setting an 85.7%
ejaculatory function rate must be achieved for surveillance to be
considered the optimal choice. Clearly, less surgical rigor is needed
with a primary retroperitoneal lymph node dissection when correcting for
the effects of chemotherapy on ejaculatory function. Despite this fact,
1-way sensitivity analysis revealed that our model is insensitive to the
ejaculatory function effects of chemotherapy. Furthermore, if the
likelihood of recurrence on surveillance is greater than 16%, primary
nerve sparing retroperitoneal lymph node dissection should again be
recommended. CONCLUSIONS: Thus, to maximize ejaculatory function for
patients with stage 1 nonseminomatous germ cell tumor a nerve sparing
primary retroperitoneal lymph node dissection should always be
performed, unless the likelihood of recurrence on surveillance is low or
the surgical skill level allows for a highly successful post
chemotherapy nerve sparing dissection.
29
UI - 12352402
AU - Beck SD; Foster RS; Bihrle R; Ulbright T; Koch MO; Wahle GR; Einhorn LH;
TI -
Donohue JP
Teratoma in the orchiectomy specimen and volume of metastasis are
predictors of retroperitoneal teratoma in post-chemotherapy
nonseminomatous testis cancer.
SO - J Urol 2002 Oct;168(4 Pt 1):1402-4
AD - Department of Urology, Indiana University School of Medicine,
Indianapolis, USA.
PURPOSE: Patients who require post-chemotherapy retroperitoneal lymph
node dissection after induction chemotherapy for metastatic testis
cancer derive therapeutic benefit from resection of teratoma but
resection of necrosis is not beneficial. We determine if the absence of
teratoma in the orchiectomy specimen is a reliable predictor of the
absence of teratoma in the retroperitoneum at post-chemotherapy
retroperitoneal lymph node dissection. MATERIALS AND METHODS: A
retrospective review of the Indiana University testis cancer data base
was performed. A total of 644 patients who underwent retroperitoneal
lymph node dissection after induction chemotherapy only were selected
for study. The presence or absence of teratoma in the orchiectomy
specimen and volume of retroperitoneal tumor were analyzed as predictors
of retroperitoneal teratoma at post-chemotherapy retroperitoneal lymph
node dissection. RESULTS: Of the patients with teratoma in the
orchiectomy specimen 85.6% had an element of teratoma in the
retroperitoneum, and of those without teratomatous elements in the
orchiectomy specimen 48% had teratoma in the retroperitoneum (p
<0.00001). Increasing volumes of retroperitoneal tumor were associated
with a higher probability of discovering teratoma at post-chemotherapy
retroperitoneal lymph node dissection. CONCLUSIONS: The absence of
teratoma in the orchiectomy specimen does not reliably predict the
absence of teratoma in the surgical specimen at post-chemotherapy
retroperitoneal lymph node dissection. Post-chemotherapy surgery is
indicated if retroperitoneal tumor remains after chemotherapy
irrespective of the presence or absence of teratoma in the orchiectomy
specimen.
30
UI - 12352403
AU - Richie JP
TI -
Editorial: testis cancer--paradigm for reduction in morbidity without
sacrifice of efficacy.
SO - J Urol 2002 Oct;168(4 Pt 1):1405
31
UI - 12352451
AU - Granata C; Rizzo A; Carlini C; Gambini C; Magnano G; Conte M
TI -
Primary paratesticular neuroblastoma.
SO - J Urol 2002 Oct;168(4 Pt 1):1530-1
AD - Department of Surgery, Giannini Gaslini Children's Hospital, Genoa,
Italy.
32
UI - 11425975
AU - Bach AM; Hann LE; Hadar O; Shi W; Yoo HH; Giess CS; Sheinfeld J; Thaler
TI -
H
Testicular microlithiasis: what is its association with testicular
cancer?
SO - Radiology 2001 Jul;220(1):70-5
AD - Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275
York Ave, New York, NY 10021, USA. bacha@mskcc.org
PURPOSE: To determine the prevalence of testicular microlithiasis in
patients who were referred for scrotal ultrasonography (US) at a
tertiary care cancer center and to evaluate the association between
microlithiasis and cancer. MATERIALS AND METHODS: Testicular sonograms
obtained in 528 men were retrospectively reviewed to identify patients
with US findings suggestive of microlithiasis, intratesticular masses,
and intratesticular heterogeneous changes. The association of US
findings with medical records and with histopathologic findings that
were available in 95 patients was evaluated. Statistical analysis was
performed to determine the relationship of testicular cancer,
intratesticular mass, and microlithiasis. RESULTS: Forty-eight (9%) of
the 528 patients had microlithiasis; 13 of these (27%) had testicular
cancers. Of the 480 patients without microlithiasis, 38 (8%) had
testicular cancer. Ninety patients had an intratesticular mass, of whom
23 (26%) had microlithiasis. Forty-three (12 with microlithiasis)
patients with a mass had testicular cancer, 43 (10 with microlithiasis)
had benign findings or nontesticular malignant histopathologic findings,
and four (one with microlithiasis) had no pathologic findings.
CONCLUSION: Intratesticular microlithiasis is highly associated with
confirmed testicular cancer, as well as with US evidence of testicular
mass.
33
UI - 12218862
AU - Thoumas D; Caty A; Gobet F; Lemaitre L
TI -
[Imaging of testicular tumors]
SO - J Radiol 2002 Jun;83(6 Pt 2):883- 93, discussion 894-6
AD - CHU de Rouen, Hopital Charles Nicolle, Service de Radiologie,
Departement central d'imagerie, 1, rue de Germont, 76031 Rouen cedex,
France.
Testicular cancer is the most common malignancy in young men and its
incidence is increasing. The overall rate of cure can exceed 90% when
management is optimal. Ultrasonography for diagnosis and
thoraco-abdominal CT for staging are the optimal imaging modalities. In
this paper we analyze technical parameters as well as findings and the
strategy of examinations in testicular neoplasm.
34
UI - 12237772
AU - Berney DM; Shamash J; Gaffney J; Jordan S; Oliver RT
TI -
DNA topoisomerase I and II expression in drug resistant germ cell
tumours.
SO - Br J Cancer 2002 Sep 9;87(6):624-9
AD - Department of Histopathology and Morbid Anatomy, St Bartholomew's
Hospital, Queen Mary's School of Medicine and Dentistry, London EC1 7BE,
UK. D.Berney@bartsandthelondon.nhs.uk
A small number of testicular germ cell tumours are refractory to current
chemotherapy regimens. DNA topoisomerase I is the target for several new
drugs and a potential candidate treatment for chemorefractory germ cell
tumours. DNA topoisomerase II alpha is the target for etoposide, which
is currently used regularly in germ cell tumour treatment. The
expression of DNA topoisomerase I and II alpha were therefore assessed
immunohistochemically in a range of testicular tumours, especially those
with persistent malignant elements on retroperitoneal lymph node
dissection. Pre-chemotherapy orchidectomy specimens were matched with
post-chemotherapy retroperitoneal lymph node dissections to examine
changes in expression. There was considerable variation in the
expression of topoisomerase I in different tumour types. Both yolk sac
tumours and teratoma, mature showed universal expression of
topoisomerase I, while 38% of seminomas and 30% of embryonal carcinomas
were positive. Strong topoisomerase II alpha expression was found in
embryonal carcinoma. There was a negative correlation between
topoisomerase I and II alpha expression (P=0.004) and downregulation of
topoisomerase II alpha after chemotherapy (P=0.02). Topoisomerase I
expression appears to increase in those cases with residual teratoma,
mature, but is largely unchanged in those cases remaining as embryonal
carcinoma. These results suggest that topoisomerase I inhibitors may be
useful in chemorefractory germ cell tumours, especially yolk sac tumours
and where there are unresectable residual teratoma, mature deposits.
35
UI - 11796908
AU - Woodward PJ; Sohaey R; O'Donoghue MJ; Green DE
TI -
From the archives of the AFIP: tumors and tumorlike lesions of the
testis: radiologic-pathologic correlation.
SO - Radiographics 2002 Jan-Feb;22(1):189-216
AD - Department of Radiologic Pathology, Armed Forces Institute of Pathology,
6825 16th St, NW, Bldg 54, Rm M-121, Washington, DC 20306-6000, USA.
woodward@afip.osd.mil
Testicular carcinoma represents only 1% of all neoplasms in men, but it
is the most common malignancy in the 15-34-year-old age group. Germ cell
tumors constitute 95% of all testicular tumors. Germ cell tumors are a
varied group of neoplasms whose imaging features reflect their
underlying histologic characteristics. Seminomas are generally
well-defined homogeneous lesions, whereas the nonseminomatous tumors
(embryonal carcinoma, yolk sac tumor, choriocarcinoma, teratoma, and
mixed germ cell tumor) have a much more varied appearance. Germ cell
tumors follow a predictable pattern of spread via the lymphatic drainage
to the retroperitoneal nodes. Choriocarcinoma, which has a proclivity
for early hematogenous spread, is a notable exception. Testicular tumors
may also arise from the sex cords (Sertoli cells) and stroma (Leydig
cells). Although 90% of these tumors are benign, there are no reliable
imaging criteria to differentiate them from malignant masses. Some
benign testicular masses can be recognized, obviating an unwarranted
orchiectomy. A dilated rete testis is a normal variant and appears as a
series of small tubules near the mediastinum testis. Other benign
lesions that can be suspected on the basis of imaging findings and
history include intratesticular cysts, epidermoid cysts, congenital
adrenal hyperplasia, and sarcoidosis. Copyright RSNA, 2002
36
UI - 12074782
AU - Dieckmann KP; Lauke H; Michl U; Winter E; Loy V